Form 4: Enliven COO Sells Shares Under 10b5-1 Plan
Statement of Changes in Beneficial Ownership
Enliven Therapeutics' Chief Operating Officer, Anish Patel, sold 6,663 shares of common stock on December 8, 2025, through a pre-arranged Rule 10b5-1 trading plan.
Summary
- Anish Patel, Chief Operating Officer of Enliven Therapeutics, Inc. (ELVN), sold a total of 6,663 shares of common stock.
- The sales occurred on December 8, 2025.
- The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024, by Anish Patel and The Patel / Dong Family Trust Dated August 24, 2017.
- One transaction involved the direct sale of 4,958 shares at a weighted average price of $20.7622 per share, with prices ranging from $20.51 to $21.495.
- A second transaction involved the direct sale of 1,705 shares at a weighted average price of $21.7794 per share, with prices ranging from $21.51 to $22.055.
- Following these direct sales, Anish Patel indirectly beneficially owns 263,311 shares held by The Patel / Dong Family Trust, for which he serves as trustee.
Sentiment
Score: 5
Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, the transaction was conducted under a pre-arranged 10b5-1 trading plan, which mitigates concerns about opportunistic selling based on non-public information. It represents a routine personal financial management activity for an executive.
Negatives
- Chief Operating Officer Anish Patel reduced his direct ownership in the company by selling 6,663 shares.
Risks
- Insider selling, even under a 10b5-1 plan, can sometimes be perceived by the market as a lack of confidence, potentially leading to negative investor sentiment.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
This Form 4 filing reports a routine insider stock transaction under a pre-arranged trading plan, which is a common practice for executives to manage personal finances and diversify holdings while complying with insider trading regulations. It does not provide information on broader industry trends or competitive landscape.
Related Party Transactions
- The sales were made by Anish Patel, the Chief Operating Officer, and also by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee. The indirect beneficial ownership is held by this trust.
Stakeholder Impact
- Shareholders: A slight reduction in direct insider ownership, though mitigated by the 10b5-1 plan. The market may interpret this as a routine diversification or personal liquidity event.
Key Dates
| Date | Description |
|---|---|
| 2024-09-30 | Adoption date of the Rule 10b5-1 trading plan by Anish Patel and The Patel / Dong Family Trust. |
| 2025-12-08 | Date of reported stock sales by Anish Patel. |
| 2025-12-10 | Signature date of the Form 4 filing. |
Keywords
Enliven Therapeutics, ELVN, Anish Patel, Chief Operating Officer, COO, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Beneficial Ownership, Equity Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.